Literature DB >> 405043

Enzymological properties and immunological characterization of alpha-galactosidase isoenzymes from normal and Fabry human liver.

A W Schram, M N Hamers, B Brouwer-Kelder, W E Donker-Koopman, J M Tager.   

Abstract

1. A method is described for the rapid isolation of alpha-galactosidases A and B (alpha-D-galactoside galactohydrolase, EC 3.2.1.22) from normal human liver. 2. When the same method is applied to Fabry liver, most of the alpha-galactosidase activity is recovered in the fraction corresponding to normal alpha-galactosidase B. In agreement with Romeo, G., D'Urso, M., Pisacane, A., Blum, E., De Falco, A. and Ruffilli, A. (1975) Biochem. Genet. 13, 615-628) [18], a small amount of alpha-galactosidase activity is found in the fraction corresponding to normal alpha-galactosidase A. 3. The kinetic properties of the B-like activity from Fabry liver are similar to those of normal alpha-galactosidase B. In agreement with Romeo et al. [18], it was found that the kinetic properties of the A-like activity from Fabry liver are similar to those of normal alpha-galactosidase A. 4. Using antisera raised against normal alpha-galactosidase A and normal alpha-galactosidase B, it is shown that the normal alpha-galactosidase isoenzymes are immunologically distinct and that the B-like activity from Fabry liver is immunologically related to normal alpha-galactosidase B. Furthermore, the A-like activity from Fabry liver is immunologically related to normal alpha-galactosidase B and not to normal alpha-galactosidase A. 5. Normal alpha-galactosidase B is converted into an A-like form during storage. 6. It is concluded that the B-like alpha-galactosidase in Fabry tissues is identical to normal alpha-galactosidase B, and that the small amount of A-like activity found in Fabry material is due to a modified form of alpha-galactosidase B.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 405043     DOI: 10.1016/0005-2744(77)90360-6

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Binding interactions of glycoproteins with lectins.

Authors:  J T Dulaney
Journal:  Mol Cell Biochem       Date:  1978-10-13       Impact factor: 3.396

2.  The genetic defect in the various types of human beta-galactosidase deficiency.

Authors:  H L Hoeksema; J De Wit; A Westerveld
Journal:  Hum Genet       Date:  1980-02       Impact factor: 4.132

3.  Characterization of alpha-galactosidase isoenzymes in normal and Fabry human-Chinese Hamster somatic cell hybrids.

Authors:  M N Hamers; A Westerveld; M Khan; J M Tager
Journal:  Hum Genet       Date:  1977-05-10       Impact factor: 4.132

4.  A new immunochemical method for the quantitative measurement of specific gene products in man-rodent somatic cell hybrids.

Authors:  P G de Groot; M N Hamers; A Westerveld; A W Schram; P Meera Khan; J M Tager
Journal:  Hum Genet       Date:  1978-11-16       Impact factor: 4.132

5.  Characterization of gana-1, a Caenorhabditis elegans gene encoding a single ortholog of vertebrate alpha-galactosidase and alpha-N-acetylgalactosaminidase.

Authors:  Jana Hujová; Jakub Sikora; Robert Dobrovolný; Helena Poupetová; Jana Ledvinová; Marta Kostrouchová; Martin Hrebícek
Journal:  BMC Cell Biol       Date:  2005-01-27       Impact factor: 4.241

6.  Multiple exo-glycosidases in human serum as detected with the substrate DNP-α-GalNAc. I. A new assay for lysosomal α-N-acetylgalactosaminidase.

Authors:  Simon P J Albracht; Erik Allon; Johannes van Pelt
Journal:  BBA Clin       Date:  2017-10-07

7.  Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease.

Authors:  Kassiani Kytidou; Thomas J M Beenakker; Lotte B Westerhof; Cornelis H Hokke; Geri F Moolenaar; Nora Goosen; Mina Mirzaian; Maria J Ferraz; Mark de Geus; Wouter W Kallemeijn; Herman S Overkleeft; Rolf G Boot; Arjen Schots; Dirk Bosch; Johannes M F G Aerts
Journal:  Front Plant Sci       Date:  2017-06-21       Impact factor: 5.753

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.